ABSTRACT
Gamma scintigraphy is often used to quantify deposition patterns from aerosol inhalers. The errors caused by scatter and tissue attenuation in planar Tc-99m gamma scintigraphy were investigated based on the data collected from four subjects in this study. Several error correction methods were tested. The results from two scatter correction methods, Jaszczak's method and factor analysis of dynamic sequences (FADS), were similar. Scatter accounted for 20% of raw data in the whole lung, 20% in the oropharynx, and 43% in the central airways and esophagus. Three attenuation correction methods were investigated and compared. These were: uniform attenuation correction (UAC), a known method used for inhalation drug imaging work; the broad-beam attenuation correction used for organ imaging in nuclear medicine; and a narrow-beam inhomogeneous tissue attenuation correction proposed in this study. The three methods differed significantly (p < 0.05), but all indicated that attenuation is a severe quantification problem. The narrow beam attenuation correction with scatter correction, showed that raw data underestimated tracer deposition by 44% in the lung, 137% in the oropharynx, and 153% in the trachea/esophageal region. To quantify aerosol lung deposition using planar scintigraphy even in relative terms, corrections are necessary. Much of the literature concerning quantified aerosol dose distributions measured by gamma scintigraphy needs to be interpreted carefully.
Subject(s)
Aerosols/pharmacokinetics , Anti-Inflammatory Agents/administration & dosage , Anti-Inflammatory Agents/pharmacokinetics , Esophagus/drug effects , Lung/drug effects , Oropharynx/drug effects , Radionuclide Imaging/standards , Technetium , Trachea/drug effects , Triamcinolone Acetonide/administration & dosage , Triamcinolone Acetonide/pharmacokinetics , Administration, Inhalation , Adult , Bias , Data Interpretation, Statistical , Factor Analysis, Statistical , Humans , Male , Middle Aged , Nebulizers and Vaporizers , Particle Size , Radionuclide Imaging/instrumentation , Radionuclide Imaging/methods , Scattering, Radiation , Technetium/pharmacokinetics , Tissue DistributionABSTRACT
PURPOSE: We performed a crossover study to determine the relative pharmacokinetic bioavailability and antidiuretic activity of desmopressin in 16 orally hydrated, healthy human subjects. MATERIALS AND METHODS: The investigation included 5 study periods with 1 period used to establish baseline diuresis in the absence of desmopressin and the remaining 4 randomized to a single 0.6 mg. oral dose of desmopressin administered as whole, crushed or chewed tablets, or as an oral solution. Serial plasma samples were collected for 12 hours for desmopressin pharmacokinetic analysis. Pharmacodynamics were assessed by measuring changes in urine volume and osmolality from baseline. Standard bioequivalence metrics were used to compare the pharmacokinetics and pharmacodynamics of crushed and chewed tablets, and oral solution to that of swallowing whole tablets. RESULTS: The 90% confidence interval analysis of log transformed plasma desmopressin area under the plasma concentration-time curve from time 0 to infinity and maximum plasma drug concentration showed that crushed and chewed tablet treatments were bioequivalent to swallowing whole tablets. The 90% confidence interval analysis for the decrease in urine volume and increase in urine osmolality demonstrated that crushed and chewed tablets, and oral solution treatments were equivalent to whole tablet treatment in the area under curve from time 0 to the last sampling time point and maximum drug effect. CONCLUSIONS: The results of this study imply that desmopressin administered orally as crushed or chewed tablets, or as an oral solution has the same net effect on decreasing urine volume and increasing urine osmolality as swallowing tablets whole.
Subject(s)
Deamino Arginine Vasopressin/administration & dosage , Deamino Arginine Vasopressin/pharmacokinetics , Renal Agents/administration & dosage , Renal Agents/pharmacokinetics , Administration, Oral , Adult , Biological Availability , Cross-Over Studies , Deamino Arginine Vasopressin/pharmacology , Diuresis/drug effects , Humans , Male , Middle Aged , Osmolar Concentration , Renal Agents/pharmacology , Solutions , Tablets , Therapeutic Equivalency , UrineABSTRACT
The intense inherent electron-capture properties of the C21 acetate derivative of triamcinolone acetonide (TAA) under methane chemical ionization mass spectrometric conditions were exploited for the development of a highly sensitive and selective gas chromatography-mass spectrometric (GC-MS) technique for measurement of levels of TAA in human bronchoalveolar lavage (BAL) fluid. After the addition of 3.0 ng of a heptadeuterated analog of TAA and varying concentrations of TAA to 2-ml aliquots of BAL fluid, the deuterium and protium forms of the steroid were extracted with diethyl ether, converted to the C21 acetate derivative, and purified via adsorptive chromatography prior to GC-MS analysis. Standard curves obtained from 2-ml aliquots of BAL fluid were linear over a wide range of concentrations of TAA from 0.0 to 24,600 pg/2-ml aliquots of BAL fluid. Levels as low as 6.0 pg/ml (13.8 pmol x L(-1)) in BAL fluid can be reliably determined in 2-ml aliquots of the biological fluid with <10% error. These findings suggest that the assay method exploiting the intense electron-capture properties of TAA is highly suitable for determination of the deposition pattern and in vivo kinetics of TAA in human airways following inhalation of the steroid.
Subject(s)
Bronchoalveolar Lavage Fluid/chemistry , Gas Chromatography-Mass Spectrometry , Triamcinolone Acetonide/analysis , Humans , Molecular Structure , Nasal Mucosa/chemistry , Triamcinolone Acetonide/analogs & derivativesABSTRACT
UNLABELLED: Triamcinolone acetonide (TAA) is an anti-inflammatory steroid used for topical treatment of allergic rhinitis and asthma. Drug deposition onto target tissues is an important parameter, so methods for accurate deposition measurement are needed. Lung deposition is especially problematic to measure because of the large field of view and low relative drug penetration. Our main objective was to use PET to measure the deposition and postdeposition kinetics of TAA in the lung after administration from the Azmacort inhaler. The second objective was to evaluate changes in distribution caused by the inhalation spacer that is built into the product. METHODS: 11C-labeled TAA was formulated as the Azmacort product, 5 healthy volunteers inhaled it, and PET scans were obtained of its distribution in the head and chest. Region-of-interest analysis with CT overlay was used to analyze the distribution and kinetics in the airway and lung. RESULTS: From 10% to 15% of the inhaled drug dose was deposited in target airway regions in a distally decreasing pattern. Deposition in the oral cavity was about 30% of the dose. Slow absorption or clearance of drug from target tissues was observed over time. Use of the inhalation spacer caused statistically significant increases in all target tissues (factor of 2-5) and a roughly 40% decrease in oral deposition. Measurable amounts of the drug remained in target regions throughout the scanning period. CONCLUSION: Local pulmonary distribution and kinetics of inhaled drugs can be measured accurately by PET for drug development. The integrated actuator-spacer significantly enhanced deposition of TAA in target tissues and reduced deposition in the oropharyngeal region.
Subject(s)
Anti-Inflammatory Agents/pharmacokinetics , Lung/diagnostic imaging , Tomography, Emission-Computed , Triamcinolone Acetonide/pharmacokinetics , Administration, Inhalation , Adult , Anti-Inflammatory Agents/administration & dosage , Carbon Radioisotopes , Humans , Image Processing, Computer-Assisted , Lung/metabolism , Male , Nebulizers and Vaporizers , Oropharynx/diagnostic imaging , Oropharynx/metabolism , Radiopharmaceuticals/pharmacokinetics , Tissue Distribution , Tomography, X-Ray Computed , Triamcinolone Acetonide/administration & dosageABSTRACT
Drug biodistribution is often secondary to drug action. However, drugs that have a topical action and are deposited into the airway by inhalation are dependent on effective deposition at the intended site of action. Measurement of the distribution of such drugs in the airway is a useful tool. Distribution data can help to interpret clinical results, to evaluate products relative to each other, to optimize a new drug formulation, and to choose effective drug delivery methods. Imaging of radiotracers is the only means available to measure drug deposition throughout the lungs, nasal passages, and sinuses. There are several approaches to imaging drug deposition. Planar imaging has been the most used method, but SPECT and PET imaging are beginning to be applied effectively. The properties of non-drug tracers, labeling of drugs, evaluation of distribution patterns, and quantification of deposited drugs are important issues that have been addressed. Imaging has been shown to be a powerful technique to evaluate and to speed development of inhaled drugs. This review explores the most recent advances and issues with an emphasis on drug development.
Subject(s)
Pharmacokinetics , Tomography, Emission-Computed, Single-Photon , Tomography, Emission-Computed , Administration, Inhalation , Animals , Humans , Tissue DistributionABSTRACT
The principle objective of this study was to characterize the absorption, metabolism, and disposition of orally administered [14C]-triamcinolone acetonide. Six healthy male subjects each received a single 100 microCi (approximately 800 micrograms) oral dose of [14C]-triamcinolone acetonide. Plasma, urine, and fecal samples were collected at selected times and analyzed for triamcinolone acetonide and [14C]-derived radioactivity. Plasma protein binding of triamcinolone acetonide was also determined. Metabolite profiling and identification were carried out in plasma and excreta. Principle metabolites were assessed for activity with in vitro anti-inflammatory models. [14C]-triamcinolone acetonide was found to be systemically absorbed following oral administration. The presystemic metabolism and clearance of triamcinolone acetonide were extensive, with only a small fraction of the total plasma radioactivity being made up of triamcinolone acetonide. Little to no parent compound was detected in the plasma 24 hours after administration. Most of the urinary and fecally [14C]-derived radioactivity was also excreted within 24 and 72 hours postdose, respectively. Mean plasma protein binding of triamcinolone acetonide was constant, predictable, and a relatively low 68% over a 24-fold range of plasma concentrations. Three principle metabolites of triamcinolone acetonide were profiled in plasma, urine, and feces. These metabolites were identified as 6 beta-hydroxy triamcinolone, 21-carboxylic acid triamcinolone acetonide, and 6 beta-hydroxy-21-oic triamcinolone acetonide. All three metabolites failed to show any concentration-dependent effects in anti-inflammatory models evaluating IL-5-sustained eosinophil viability and IgE-induced basophil histamine release.
Subject(s)
Anti-Inflammatory Agents/pharmacokinetics , Triamcinolone Acetonide/pharmacokinetics , Administration, Oral , Adolescent , Adult , Anti-Inflammatory Agents/metabolism , Anti-Inflammatory Agents/pharmacology , Anti-Inflammatory Agents/urine , Basophils/drug effects , Basophils/metabolism , Biotransformation , Carbon Radioisotopes , Cell Survival/drug effects , Eosinophils/cytology , Eosinophils/drug effects , Feces/chemistry , Histamine/metabolism , Humans , Male , Metabolic Clearance Rate , Protein Binding , Triamcinolone Acetonide/metabolism , Triamcinolone Acetonide/pharmacology , Triamcinolone Acetonide/urineABSTRACT
The impending phaseout of chlorofluorocarbons as propellants in pressurized metered-dose inhalers used in the treatment of asthma has resulted in the development of alternative devices to deliver drug to the pulmonary airways. These alternative devices include metered-dose inhalers using environmentally friendly hydroflurocarbon propellants and breath-actuated dry-powder inhalers. The purpose of this study was to compare the single- and multiple-dose pharmacokinetics, pharmacodynamics, and tolerability of a newly developed hydroflurocarbon formulation of triamcinolone acetonide (Azmacort HFA 225 mcg Inhalation Aerosol) to that of the dry-powder formulation of budesonide (Pulmicort Turbuhaler 200 mcg). This three-way crossover study used 18 normal healthy subjects each receiving a 675 mcg dose of triamcinolone acetonide, 600 mcg dose of budesonide, or placebo twice a day for 5 days. Serial plasma samples were collected after the first and last dose of test medication for pharmacokinetic analysis. Pharmacodynamics were assessed by changes in hypothalamic-pituitary-adrenal axis function as measured by 8 a.m. serum cortisol, 24-hour overnight serum cortisol AUC(0-24), and 24-hour urinary-free cortisol after the last evening dose of test drug. Tolerability was assessed through physical examinations, vital signs, 12-lead ECG, routine clinical labs, and adverse events recording. Both compounds were systemically absorbed. However, no significant drug accumulation was noted with chronic dosing. Chronic dosing did result in a statistically significant 20% reduction in basal 24-hour serum cortisol AUC(0-24) for both compounds. There were no clinically significant abnormalities in physical examination, vital signs, 12-lead ECG, or routine clinical labs noted during the study. Overall, the study drugs were well tolerated, with adverse events characterized as mild to moderate in severity.
Subject(s)
Anti-Inflammatory Agents/pharmacokinetics , Budesonide/pharmacokinetics , Hydrocarbons, Fluorinated/administration & dosage , Nebulizers and Vaporizers , Triamcinolone Acetonide/pharmacokinetics , Administration, Inhalation , Adolescent , Adult , Aerosol Propellants/administration & dosage , Analysis of Variance , Anti-Inflammatory Agents/adverse effects , Anti-Inflammatory Agents/blood , Area Under Curve , Blood Pressure/drug effects , Budesonide/adverse effects , Budesonide/blood , Cross-Over Studies , Diarrhea/chemically induced , Dizziness/chemically induced , Dose-Response Relationship, Drug , Electrocardiography , Headache/chemically induced , Humans , Hydrocortisone/blood , Hydrocortisone/urine , Male , Pulse , Triamcinolone Acetonide/adverse effects , Triamcinolone Acetonide/bloodABSTRACT
The three dimensional (3D) distribution of inhaled drugs was measured using Positron Emission Tomography (PET) (Berridge, M.S, Muswick, G.J., Lee, Z., Leisure, G.L., Nelson, A.D., Muzic, R.F. Jr., Miraldi, F., Heald, D.L., 1997. PET evaluation of Azmacort(R) ([C-11]triamcinolone acetonide) dose administration. J. Nucl. Med. 38 (5) Suppl., 4-5). Data analysis was based upon regional ratios or penetration indices. To improve the analytical usefulness and objectivity, labeled drug from dynamic PET images was mapped into 23 airway generations following a general framework from a SPECT-based methodology (Fleming, J.S., Nassim, M.A., Hashish, A.H., Bailey, A.G. , Conway, J., Holgate, S., Halson, P., Moore, E., Martonen, T.B., 1995. Description of pulmonary deposition of radiolabeled aerosol by airway generation using a conceptual three dimensional model of lung morphology. J. Aerosol Med. 8, 341-356). A recently developed airway network model was used in this study. Quantitative PET scans of [C-11]triamcinolone acetonide distribution in the lung were determined following administration of Azmacort(R), a commercial metered dose inhaler with an integrated spacer device. Distributions at varying time periods after drug administration were investigated to explore the dynamics and kinetics of the aerosolized drug. Initially, deposition of labeled drug on conducting airways (generations 1-14) was found to be higher than those on acinar airways (generation 15-23), 64% versus 36%. The distribution pattern changed slowly with time. By 47 min, 51% of the dose remaining in the lung was found on conducting airways while 49% was on acinar airways. This study illustrates the value of PET imaging for the evaluation and design of drug formulations.
Subject(s)
Anti-Inflammatory Agents/pharmacokinetics , Respiratory System/metabolism , Triamcinolone Acetonide/pharmacokinetics , Aerosols , Algorithms , Anti-Inflammatory Agents/administration & dosage , Humans , Models, Anatomic , Particle Size , Respiratory System/diagnostic imaging , Tomography, Emission-Computed , Tomography, X-Ray Computed , Triamcinolone Acetonide/administration & dosageSubject(s)
Antihypertensive Agents/pharmacokinetics , Delayed-Action Preparations/pharmacokinetics , Digestive System/diagnostic imaging , Digestive System/metabolism , Diltiazem/pharmacokinetics , Adult , Cross-Over Studies , Dietary Fats , Evaluation Studies as Topic , Fasting , Humans , Neutron Activation Analysis , Radioisotopes , Radionuclide Imaging , Samarium , TabletsSubject(s)
Administration, Inhalation , Tomography, Emission-Computed/methods , Anti-Inflammatory Agents/administration & dosage , Anti-Inflammatory Agents/pharmacokinetics , Cross-Over Studies , Humans , Nasal Mucosa/metabolism , Respiratory System/metabolism , Triamcinolone Acetonide/administration & dosage , Triamcinolone Acetonide/pharmacokineticsABSTRACT
Triamcinolone acetonide is a glucocorticoid administered by oral inhalation in the management of asthma. With oral inhalation of glucocorticoids, systemic absorption can come from oropharyngeal, gastrointestinal, or airway deposition of the drug. The objectives of this study were to determine the absolute bioavailability of triamcinolone acetonide following inhalation administration and to delineate the airway contribution of triamcinolone acetonide absorption relative to the absolute bioavailability. All subjects received a 5-minute 400 mcg intravenous infusion of triamcinolone acetonide and a single 800 mcg dose of inhaled triamcinolone acetonide with and without oral charcoal administration in a randomized three-way crossover fashion. The oral charcoal allowed for isolating the pulmonary component of absorption by adsorbing the oropharyngeal and gastrointestinal deposited drug. The mean (+/- SD) absolute bioavailability value for inhaled triamcinolone acetonide was 25% (8.75%). Delineation of the airway contribution of triamcinolone acetonide absorption showed that 10.4% of an inhaled dose is absorbed as triamcinolone acetonide from the lungs. Mean (+/- SD) total body clearance was rapid at 0.57 (0.12) L/hr/kg. The mean (+/- SD) apparent volume of distribution following the intravenous dose was a low 1.96 (0.31) L/kg. No significant differences were noted in the apparent terminal elimination half-life of triamcinolone acetonide (approximately 2.4 hr) between treatments.
Subject(s)
Glucocorticoids/pharmacokinetics , Triamcinolone Acetonide/pharmacokinetics , Administration, Inhalation , Adolescent , Adult , Analysis of Variance , Area Under Curve , Biological Availability , Humans , Infusions, Intravenous , Male , Metabolic Clearance Rate , Patient DropoutsABSTRACT
UNLABELLED: PET is a technique with a strong potential for use in drug evaluation and development. In particular, the distribution and pharmacokinetics of locally administered drugs may be advantageously explored noninvasively using labeled compounds. This pilot study was performed to demonstrate the effectiveness of PET for drug development and to determine the human biodistribution and kinetics of triamcinolone acetonide, labeled with 11C, formulated and nasally administered as Nasacort AQ nasal inhalant. METHODS: Carbon-11-labeled triamcinolone acetonide was formulated as the commercial product, and PET scans of the heads of four volunteers were performed in a vertical orientation. Region-of-interest analysis with MRI coregistration was used to analyze the distribution and kinetics in nasal tissues. RESULTS: Deposition of the majority of the dose on target tissues was immediate. Penetration into sinuses was observed. There was moderate redistribution and slow migration of the drug through nasal passages to the throat. Significant amounts of the drug remained in target regions for several hours. CONCLUSION: PET is an effective means to determine local drug distribution and kinetics.
Subject(s)
Anti-Inflammatory Agents/pharmacokinetics , Carbon Radioisotopes , Tomography, Emission-Computed , Triamcinolone Acetonide/pharmacokinetics , Administration, Inhalation , Adult , Anti-Inflammatory Agents/administration & dosage , Feasibility Studies , Female , Humans , Nasal Mucosa/metabolism , Tissue Distribution , Triamcinolone Acetonide/administration & dosageABSTRACT
The objective of this study was to compare the single- and multiple-dose pharmacokinetics and electrocardiographic effect of a 10-mg oral dose of ebastine in elderly (ages, 65-85 years) and young (ages, 18-35 years) healthy volunteers. Thirty-seven subjects completed this randomized, double-blind, multiple-dose, placebo-controlled, parallel group study. The elderly group consisted of 18 subjects, with 13 subjects receiving 10 mg ebastine and 5 receiving matching placebo. The young group consisted of 19 subjects, with 13 subjects receiving 10 mg ebastine and 6 receiving matching placebo. On study days 1 and 3 through 10, each subject received a single 10-mg dose of ebastine or matching placebo in the morning with a standard breakfast. No drug was administered on study day 2 because of pharmacokinetic sampling. Blood samples were collected at selected times postdose on study days 1, 2, and 10. Plasma samples were analyzed for ebastine and its active metabolite, carebastine, using a validated high-performance liquid chromatography method. No plasma ebastine concentrations were detected, suggesting essentially complete metabolic conversion of ebastine to its metabolites. Analysis of variance showed no statistically significant differences between young and elderly single- and multiple-dose carebastine pharmacokinetics with respect to area under the plasma concentration-time curve, maximum concentration (Cmax ), terminal elimination rate constant, apparent oral clearance, or apparent volume of distribution. The mean time of maximum concentration value for young subjects was 1 hour longer than that for elderly subjects after single-dose administration but was comparable after multiple-dose administration. Within-group comparisons of both the young and elderly showed that pharmacokinetics between single dose and steady state were not statistically different. However, the mean steady-state carebastine Cmax values were approximately twofold greater than the mean Cmax values obtained after single-dose administration. A twofold increase in Cmax values between single-dose and steady-state administration is predicted for drugs such as carebastine, because its input interval is approximately equal to its elimination half-life. Twelve-lead electrocardiography was performed before dosing on day 1 and repeated 4 hours postdose on days 1, 5, and 10. Twenty-four hour Holter monitoring was also performed before and at the end of the study. No clinically relevant findings were found by electrocardiography or Holter monitoring between ebastine and placebo in the elderly and young subjects.
Subject(s)
Butyrophenones/pharmacokinetics , Electrocardiography/drug effects , Histamine H1 Antagonists/pharmacokinetics , Piperidines/pharmacokinetics , Administration, Oral , Adolescent , Adult , Age Factors , Aged , Aged, 80 and over , Analysis of Variance , Butyrophenones/administration & dosage , Butyrophenones/metabolism , Chromatography, High Pressure Liquid , Double-Blind Method , Drug Monitoring , Electrocardiography, Ambulatory/drug effects , Female , Histamine H1 Antagonists/administration & dosage , Histamine H1 Antagonists/metabolism , Humans , Male , Middle Aged , Piperidines/administration & dosage , Piperidines/metabolismABSTRACT
Capital charging was introduced into the National Health Service (NHS) in 1991 in order to stop capital being treated as a 'free' good and to encourage managers to use their assets more efficiently. This article seeks to examine the extent to which managerial thinking has been influenced. It uses as evidence interviews with NHS managers conducted in Scotland in 1994. The following uses of capital charges data are explored: capital programme; disposal programme; maintenance programme; contract pricing; and budgetary devolution. New capital programmes required more justification and capital charges were seen as relevant to estate rationalization. Less effect was found with regard to the maintenance programme, though this may have been due to a downgrading of the estates function in most Trusts. Although the capital charge costs included in contract prices affect the competitive position of providers, there was criticism of the lack of development of the purchasing function. Budgetary devolution was proceeding relatively slowly but, among those Trusts which had devolved capital charges, evidence was found that some clinicians were becoming aware of the full costs of equipment use. This article concludes, with cautious optimism, that capital charges are beginning to influence decisions and that, despite some incentives being dysfunctional, they will lead to a better managed NHS.
Subject(s)
Capital Expenditures , Fees and Charges , Health Facility Administrators/psychology , State Medicine/economics , Budgets , Contract Services/economics , Decision Making, Organizational , Humans , Interviews as Topic , Motivation , Program Evaluation , Scotland , State Medicine/organization & administrationABSTRACT
Two studies were performed to characterize the influence of food on the bioavailability of the current formulation of ebastine tablets. Study 1 was an open label, randomized, three-period, crossover food effect study where 18 healthy male volunteers received 10 mg ebastine after an overnight fast, a low-fat breakfast, and a high-fat breakfast. Study 2 was an open label, randomized, two period crossover food effect study where 12 healthy male volunteers received 20 mg ebastine after both an overnight fast and a high-fat breakfast. Plasma samples were obtained at selected times and analyzed for ebastine and carebastine, the active metabolite of ebastine, using a validated high-performance liquid chromatography assay. Biopharmaceutic parameters for carebastine, area under the plasma concentration-time curves (AUC (0-infinity)), and maximum plasma concentrations (C ( max ) ), were estimated using noncompartmental techniques and analyzed for statistical differences. AUC (0-infinity) and C(max estimates were 40%-50% and 30%-40% higher under fed conditions as compared with fasting conditions. The time to reach maximum concentrations (T(max)), the terminal elimination rate (K(e) ), and the half-life (t(1/2) ) were not significantly altered by the ingestion of a low-fat or high-fat meal. Statistical analyses of the natural logarithmic transformed data for AUC ((0-infinity) and C(max) also demonstrated significant differences between fasted and fed (low-fat and high-fat) conditions. This indicates that food had a statistically significant effect on the rate and extent of carebastine formation. Therefore, it may be concluded that administration with food maximizes the bioavailability of carebastine.
Subject(s)
Butyrophenones/pharmacokinetics , Histamine H1 Antagonists/pharmacokinetics , Piperidines/pharmacokinetics , Adult , Area Under Curve , Biological Availability , Butyrophenones/administration & dosage , Butyrophenones/adverse effects , Cross-Over Studies , Dietary Fats/pharmacology , Food-Drug Interactions , Half-Life , Histamine H1 Antagonists/administration & dosage , Histamine H1 Antagonists/adverse effects , Humans , Male , Middle Aged , Piperidines/administration & dosage , Piperidines/adverse effects , TabletsABSTRACT
The relationship between plasma concentrations of desmopressin and clotting factors Factor VIII:C (FVIII:C) and von Willebrand Factor (vWF) were explored after a single 15-minute intravenous infusion of desmopressin (0.3 microg/kg) to 28 healthy male subjects. Individual plasma desmopressin-vWF and desmopressin-FVIII:C concentration/response-time data were fitted to a pharmacodynamic sigmoid E ( max ) model linked to a two-compartment open pharmacokinetic model (Ke0 link). The model demonstrated that the onset rate of pharmacodynamic activity for FVIII:C and vWF was relatively rapid following intravenous administration. However, the offset rate of pharmacodynamic activity was rate-limited by the elimination rate of desmopressin. Mean maximum pharmacodynamic activity for both factors was estimated to be three- to four-times higher than baseline activity, and the mean desmopressin concentrations that produce half-maximal effects were approximately 250 to 300 pg/mL. Interindividual variation in pharmacodynamic-parameter estimates were of the magnitude that suggests a wide range of pharmacodynamic responses are possible for a fixed desmopressin dose.
Subject(s)
Deamino Arginine Vasopressin/pharmacology , Deamino Arginine Vasopressin/pharmacokinetics , Factor VIII/metabolism , Hypoglycemic Agents/pharmacology , Hypoglycemic Agents/pharmacokinetics , von Willebrand Factor/metabolism , Adolescent , Adult , Algorithms , Deamino Arginine Vasopressin/blood , Humans , Hypoglycemic Agents/blood , Infusions, Intravenous , Male , Middle Aged , Nonlinear DynamicsABSTRACT
The potential for enhanced systemic absorption of intranasal triamcinolone acetonide was explored in patients with inflamed nasal mucosa. Twelve allergic rhinitis patients with documented nasal inflammation, and 12 healthy volunteers, each received a single, therapeutic, 400-micrograms dose of triamcinolone acetonide in each nostril. Blood was obtained at fixed time points after the dose, and plasma concentrations of triamcinolone acetonide were determined by radioimmunoassay. There were no statistically significant differences in any of the derived pharmacokinetic parameters (maximum plasma triamcinolone acetonide concentrations [Cmax], time to maximum plasma triamcinolone concentrations [Tmax], elimination half-life [t1/2], and area under the plasma concentration-time curve [AUC0-12] from 0 to 12 hours) between treatment groups. A once-a-day, chronic regimen (6 weeks) of triamcinolone acetonide was also administered to five patients with allergic rhinitis. Pharmacokinetic parameters were similar to the parameters derived from healthy volunteers after acute administration. There was no evidence of drug accumulation. The results of this study indicate that acute and chronic intranasal administration. The results of this study indicate that acute and chronic intranasal administration of therapeutic doses of triamcinolone acetonide to patients with inflamed nasal mucosa does not result in enhanced systemic drug absorption or accumulation.
Subject(s)
Nasal Mucosa/metabolism , Rhinitis, Allergic, Perennial/metabolism , Triamcinolone Acetonide/pharmacokinetics , Absorption , Administration, Intranasal , Adolescent , Adult , Drug Administration Schedule , Follow-Up Studies , Half-Life , Humans , Male , Middle Aged , Triamcinolone Acetonide/blood , Triamcinolone Acetonide/pharmacologyABSTRACT
In a double-blind study, patients with mild-to-moderate hypertension were randomly assigned to receive placebo or increasing daily doses of a new sustained-release formulation of diltiazem: 180 mg, 360 mg, and 540 mg, each once daily for two weeks. The numbers of evaluable patients were 26 in the placebo group and 81 in the diltiazem group at week 2, 24 and 75 at week 4, and 23 and 65 at week 6. Changes from baseline in mean supine trough (before drug administration) systolic/diastolic blood pressures were +1.3/-2.7 mmHg after placebo and -4.7/-6.1 mmHg after diltiazem at week 2; -0.1/-1.7 mmHg after placebo and -7.2/-9.3 mmHg after diltiazem at week 4; and +0.4/-1.7 mmHg after placebo and -6.7/-10.2 mmHg after diltiazem at week 6. The changes were significantly greater after diltiazem than placebo. Increasing the daily dose of diltiazem from 360 mg to 540 mg produced more than proportional increases in mean plasma diltiazem concentrations but only minimal further reductions in blood pressure. Similar rates of adverse experiences were reported by the diltiazem-treated and placebo patients. Treatment was withdrawn in two diltiazem-treated patients because of abnormal electrocardiographic (ECG) changes that were considered to be related to the drug: elevated ST segment in one and first-degree atrioventricular block in the other. No other treatment-related ECG changes were noted. It is concluded that this new once-daily formulation of diltiazem is safe and effective in the treatment of mild-to-moderate hypertension.
Subject(s)
Diltiazem/therapeutic use , Hypertension/drug therapy , Adolescent , Adult , Aged , Blood Pressure/drug effects , Delayed-Action Preparations , Diltiazem/administration & dosage , Diltiazem/adverse effects , Double-Blind Method , Female , Humans , Male , Middle Aged , Single-Blind MethodABSTRACT
In this open-label, randomized, cross-over study, 12 healthy subjects received four doses of a new sustained-release formulation of diltiazem hydrochloride for six consecutive days. Blood samples were drawn on days 5 and 6 for determination of plasma diltiazem and desacetyldiltiazem levels. The peak concentrations after 120, 240, 360, and 480 mg of diltiazem were 48.1, 112.6, 180.9, and 276.8 ng/ml, respectively, while the mean minimum concentrations were 6.3, 14.6, 24.9, and 44.6 ng/ml. The areas under the concentration-time curves were 702, 1,642, 2,622, and 4,004 ng.hr/ml. Prolonged, continuous absorption of diltiazem was noted over the 24-hour dosing period. The dose-adjusted mean steady-state plasma diltiazem levels after the four doses were significantly different, consistent with diltiazem's nonlinear absorption, but the plasma profiles were similar, indicating that the diltiazem release rate was not dose-dependent. Therapeutic plasma diltiazem levels (greater than or equal to 40 ng/ml) were maintained for 24 hours after the three larger doses. The changes in the pharmacokinetics of desacetyldiltiazem over the four diltiazem doses were similar to those of diltiazem. The number of adverse treatment experiences tended to increase with the higher doses, but none were severe. The results indicate that, according to their pharmacokinetic profiles, doses of 240 mg to 480 mg of diltiazem are suitable for once-daily administration.
Subject(s)
Diltiazem/pharmacokinetics , Adolescent , Adult , Delayed-Action Preparations , Diltiazem/administration & dosage , Diltiazem/adverse effects , Diltiazem/blood , Drug Administration Schedule , Eating , Humans , MaleABSTRACT
The effects of gastric motility on the pharmacokinetics of cefpodoxime proxetil, an oral, broad spectrum, third-generation cephalosporin antibiotic were evaluated in 12 healthy subjects. In this open-label, crossover trial, each subject took a 200 mg dose (two 100 mg film-coated tablets) in each study period. There was an initial fasting period followed by a control period and then either a propantheline or metoclopramide period. Gastric motility was measured using [99mTc]-labeled sulfur colloid in oatmeal in the control, propantheline and metoclopramide periods. Treatment with propantheline or metoclopramide was given 30 min before dosing with the antibiotic and the radioisotope. Serial images with a gamma counter were made every 15 min for 2 h. Gastric emptying time was faster than control with metoclopramide, but generally slower with propantheline than control. The mean peak plasma concentration, mean area under plasma concentration time curve and mean half-life of cefpodoxime proxetil were similar in all groups as compared to control. The mean time to peak plasma concentration was delayed in the propantheline period and peak plasma concentrations were greater at all sampling times at six hours after dosing. This study utilized the gastric nuclear scan with modification of gastric motility by metoclopramide and propantheline and with simultaneous determination of the disposition of cefpodoxime proxetil to understand the absorption of the drug.